IBDEI0JF ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9507,1,4,0)
 ;;=4^396.3
 ;;^UTILITY(U,$J,358.3,9507,1,5,0)
 ;;=5^Aortic and Mitral Insufficiency
 ;;^UTILITY(U,$J,358.3,9507,2)
 ;;=Aortic and Mitral Insufficiency^269583
 ;;^UTILITY(U,$J,358.3,9508,0)
 ;;=429.9^^67^662^28
 ;;^UTILITY(U,$J,358.3,9508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9508,1,4,0)
 ;;=4^429.9
 ;;^UTILITY(U,$J,358.3,9508,1,5,0)
 ;;=5^Diastolic Dysfunction
 ;;^UTILITY(U,$J,358.3,9508,2)
 ;;=^54741
 ;;^UTILITY(U,$J,358.3,9509,0)
 ;;=453.79^^67^662^27
 ;;^UTILITY(U,$J,358.3,9509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9509,1,4,0)
 ;;=4^453.79
 ;;^UTILITY(U,$J,358.3,9509,1,5,0)
 ;;=5^Chr Venous Emblsm Oth Spec Veins
 ;;^UTILITY(U,$J,358.3,9509,2)
 ;;=^338251
 ;;^UTILITY(U,$J,358.3,9510,0)
 ;;=453.89^^67^662^1
 ;;^UTILITY(U,$J,358.3,9510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9510,1,4,0)
 ;;=4^453.89
 ;;^UTILITY(U,$J,358.3,9510,1,5,0)
 ;;=5^AC Venous Emblsm Oth Spec Veins
 ;;^UTILITY(U,$J,358.3,9510,2)
 ;;=^338259
 ;;^UTILITY(U,$J,358.3,9511,0)
 ;;=454.2^^67^662^85
 ;;^UTILITY(U,$J,358.3,9511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9511,1,4,0)
 ;;=4^454.2
 ;;^UTILITY(U,$J,358.3,9511,1,5,0)
 ;;=5^Varicose Veins w/Ulcer&Inflam
 ;;^UTILITY(U,$J,358.3,9511,2)
 ;;=^269821
 ;;^UTILITY(U,$J,358.3,9512,0)
 ;;=397.1^^67^662^74
 ;;^UTILITY(U,$J,358.3,9512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9512,1,4,0)
 ;;=4^397.1
 ;;^UTILITY(U,$J,358.3,9512,1,5,0)
 ;;=5^Rheumatic Disease Pulmonary Valve
 ;;^UTILITY(U,$J,358.3,9512,2)
 ;;=^269587
 ;;^UTILITY(U,$J,358.3,9513,0)
 ;;=397.0^^67^662^75
 ;;^UTILITY(U,$J,358.3,9513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9513,1,4,0)
 ;;=4^397.0
 ;;^UTILITY(U,$J,358.3,9513,1,5,0)
 ;;=5^Rheumatic Disease Tricuspid Valve
 ;;^UTILITY(U,$J,358.3,9513,2)
 ;;=^35528
 ;;^UTILITY(U,$J,358.3,9514,0)
 ;;=414.3^^67^662^17
 ;;^UTILITY(U,$J,358.3,9514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9514,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,9514,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,9514,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,9515,0)
 ;;=414.4^^67^662^16
 ;;^UTILITY(U,$J,358.3,9515,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9515,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,9515,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,9515,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,9516,0)
 ;;=425.11^^67^662^60
 ;;^UTILITY(U,$J,358.3,9516,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9516,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,9516,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,9516,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,9517,0)
 ;;=425.18^^67^662^59
 ;;^UTILITY(U,$J,358.3,9517,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9517,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,9517,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,9517,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,9518,0)
 ;;=V12.55^^67^662^54
 ;;^UTILITY(U,$J,358.3,9518,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9518,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,9518,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,9518,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,9519,0)
 ;;=454.9^^67^662^84
 ;;^UTILITY(U,$J,358.3,9519,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9519,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,9519,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,9519,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,9520,0)
 ;;=271.3^^67^663^11
 ;;^UTILITY(U,$J,358.3,9520,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,9520,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,9520,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,9520,2)
 ;;=^64790
